PL3523274T3 - Formulacje do podawania eflornityny - Google Patents

Formulacje do podawania eflornityny

Info

Publication number
PL3523274T3
PL3523274T3 PL17858939.6T PL17858939T PL3523274T3 PL 3523274 T3 PL3523274 T3 PL 3523274T3 PL 17858939 T PL17858939 T PL 17858939T PL 3523274 T3 PL3523274 T3 PL 3523274T3
Authority
PL
Poland
Prior art keywords
eflornithine
formulations
administration
Prior art date
Application number
PL17858939.6T
Other languages
English (en)
Inventor
Victor A. Levin
Noymi Yam
Alexander VAKOULA
Original Assignee
Orbus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbus Therapeutics, Inc. filed Critical Orbus Therapeutics, Inc.
Publication of PL3523274T3 publication Critical patent/PL3523274T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL17858939.6T 2016-10-06 2017-09-29 Formulacje do podawania eflornityny PL3523274T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404981P 2016-10-06 2016-10-06
PCT/US2017/054450 WO2018067401A1 (en) 2016-10-06 2017-09-29 Formulations for administration of eflornithine

Publications (1)

Publication Number Publication Date
PL3523274T3 true PL3523274T3 (pl) 2026-03-09

Family

ID=61831551

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17858939.6T PL3523274T3 (pl) 2016-10-06 2017-09-29 Formulacje do podawania eflornityny

Country Status (14)

Country Link
US (3) US10786470B2 (pl)
EP (1) EP3523274B1 (pl)
JP (3) JP7262118B2 (pl)
KR (2) KR102592801B1 (pl)
CN (2) CN117530943A (pl)
AU (2) AU2017339781B2 (pl)
CA (2) CA3038530A1 (pl)
DK (1) DK3523274T3 (pl)
ES (1) ES3058652T3 (pl)
IL (2) IL314380A (pl)
MX (1) MX390145B (pl)
NZ (2) NZ792518A (pl)
PL (1) PL3523274T3 (pl)
WO (1) WO2018067401A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3523274T3 (pl) 2016-10-06 2026-03-09 Orbus Therapeutics, Inc. Formulacje do podawania eflornityny
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
KR20250174998A (ko) 2018-03-08 2025-12-15 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
EP3836899A2 (en) 2018-08-18 2021-06-23 FTF Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
EP3836898A2 (en) * 2018-08-18 2021-06-23 FTF Pharma Private Limited Pharmaceutical suspension for oral dosage
CN109528667A (zh) * 2018-12-19 2019-03-29 石家庄海瑞药物科技有限公司 一种达克替尼药物组合物及其制备方法
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
WO2021191928A1 (en) * 2020-03-23 2021-09-30 Navin Saxena Research & Technology Pvt. Ltd. Eflornithine composition and dosage forms for the treatment of viral infection
KR20250172562A (ko) * 2023-02-17 2025-12-09 오버스 쎄라퓨틱스, 인코포레이티드 에플로르니틴의 조성물 및 사용 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330559A (en) * 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US5614557A (en) 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5851537A (en) 1996-02-02 1998-12-22 Cancer Technologies, Inc. Topical application of α-DFMO for preventing skin cancer
AU4751597A (en) * 1996-10-04 1998-04-24 Ilex Oncology, Inc. Dfmo and taxol for the treatment or prevention of breast cancer
AU5200098A (en) 1996-11-01 1998-05-29 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6646149B1 (en) 1997-07-15 2003-11-11 Nicolaas M. J. Vermeulin Polyamine analogues as therapeutic and diagnostic agents
JP2002509884A (ja) 1998-03-28 2002-04-02 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 癌の化学防御におけるｄｆｍｏ及びスリンダクの組合せ
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
CA2356929A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia
US6199698B1 (en) * 1999-12-03 2001-03-13 Alusuisse Technology & Management, Ltd. Pharmaceutical packaging with separation means
WO2001068076A2 (en) * 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6602910B2 (en) * 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
US6630511B2 (en) 2000-08-01 2003-10-07 Rolland F. Hebert Water-soluble salts of 2-difluoromethyl-2,5-diaminopentanoic acid (DFMO)
US6653351B2 (en) * 2001-08-13 2003-11-25 Board Of Regents, The University Of Texas System Adjuvant chemotherapy for anaplastic gliomas
RU2004107843A (ru) 2001-08-15 2005-04-10 Вимин Фэст Хелскеа, Инк. (Us) Композиция локального применения для фолликулярного введения ингибитора орнитино декарбоксилазы
US20030053793A1 (en) * 2001-09-20 2003-03-20 Peter Holzmann Analog/digital recording and playback system and related method
US6998502B1 (en) * 2002-09-05 2006-02-14 Sabinsa Corporation Convenient process of manufacture for difluoromethylornithine and related compounds
US6936318B2 (en) * 2003-09-17 2005-08-30 Reynolds Metals Company No tear pharmaceutical pouch
US7754897B2 (en) 2005-06-15 2010-07-13 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
US8673366B2 (en) 2004-06-14 2014-03-18 Kareem I. Batarseh Chemotherapeutic and prophylactic pharmaceutical compositions
SE0401871D0 (sv) 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
US20080300303A1 (en) * 2005-04-15 2008-12-04 Klaus Huse Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents
WO2007075673A1 (en) 2005-12-20 2007-07-05 University Of Hawaii Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
US20070246057A1 (en) * 2006-04-20 2007-10-25 Muller Sigfrid A Ear treatment for excess hair
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
WO2010028058A1 (en) 2008-09-02 2010-03-11 Oklahoma Medical Research Foundation 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
ES2755139T3 (es) 2008-09-03 2020-04-21 Univ Johns Hopkins Alteraciones genéticas en la citrato deshidrogenasa y otros genes en gliomas malignos
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
CN101898978A (zh) * 2009-05-31 2010-12-01 徐锋 依氟鸟氨酸前药和偶合物及其使用方法
EP2521777B1 (en) 2010-01-05 2016-12-28 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma gbm
JP6122868B2 (ja) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
CN106986869A (zh) 2012-04-17 2017-07-28 吉利德科学公司 用于抗病毒治疗的化合物和方法
US20190046484A1 (en) * 2015-02-12 2019-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
EP3368029A1 (en) * 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
WO2017075576A1 (en) * 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
US20190133985A1 (en) 2016-03-24 2019-05-09 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
US20170273926A1 (en) 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
PL3523274T3 (pl) * 2016-10-06 2026-03-09 Orbus Therapeutics, Inc. Formulacje do podawania eflornityny
EP3968971A1 (en) * 2019-05-17 2022-03-23 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis

Also Published As

Publication number Publication date
JP2019534265A (ja) 2019-11-28
CN110191876A (zh) 2019-08-30
NZ752894A (en) 2023-05-26
AU2022202162B2 (en) 2024-08-15
US10786470B2 (en) 2020-09-29
IL265856A (en) 2019-06-30
DK3523274T3 (da) 2025-11-17
IL314380A (en) 2024-09-01
CA3038530A1 (en) 2018-04-12
CN117530943A (zh) 2024-02-09
NZ792518A (en) 2023-04-28
KR20220162869A (ko) 2022-12-08
US11439612B2 (en) 2022-09-13
KR20190084960A (ko) 2019-07-17
CA3176428A1 (en) 2018-04-12
JP2024153889A (ja) 2024-10-29
KR102473491B1 (ko) 2022-12-05
IL265856B1 (en) 2024-08-01
AU2017339781A1 (en) 2019-05-16
MX2019003981A (es) 2019-06-10
EP3523274A1 (en) 2019-08-14
ES3058652T3 (en) 2026-03-12
MX390145B (es) 2025-03-20
KR102592801B1 (ko) 2023-10-20
WO2018067401A1 (en) 2018-04-12
JP2023040218A (ja) 2023-03-22
AU2017339781B2 (en) 2022-03-17
JP7539175B2 (ja) 2024-08-23
JP7262118B2 (ja) 2023-04-21
US20210038549A1 (en) 2021-02-11
EP3523274A4 (en) 2020-05-13
US20230338317A1 (en) 2023-10-26
IL265856B2 (en) 2024-12-01
AU2022202162A1 (en) 2022-04-21
US20200138758A1 (en) 2020-05-07
EP3523274B1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
IL287947A (en) Viscosity reduction of pharmaceutical preparations
IL265856A (en) Preparations for the administration of aflornithine
SI4070788T1 (sl) Farmacevtske formulacije
ZA201903101B (en) Pharmaceutical formulations
IL256491A (en) Pharmaceutical formulations
PT3474822T (pt) Formulações de brincidofovir
GB201522764D0 (en) Formulations of phosphate derivatives
IL272857A (en) Cofanalisib formulations
IL256115A (en) Pharmaceutical formulations of injectable lapmoline
ZA201707094B (en) Pharmaceutical formulations
IL267279A (en) Pharmaceutical formulations of suvorexant
PT3678644T (pt) Formulações de copanlisib
IL258420A (en) Stable formulations of fingolimod
ZA201705329B (en) Pharmaceutical formulations of racecadotril
HK40012580A (en) Formulations for administration of eflornithine
HK40014181A (en) Pharmaceutical formulations of suvorexant
GB201417646D0 (en) Formulations of phosphate derivatives
GB201610440D0 (en) Pharmaceutical formulations
AU2015903141A0 (en) Controlled release formulations of paracetamol